Search Result

Results for "

organ protection

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Angiotensin Receptor (1) Biochemical Assay Reagents (1) Bradykinin Receptor (1) Calcium Channel (6) CDK (1) Cyclin G-associated Kinase (GAK) (1) Drug Derivative (2) Erythropoietin Receptor (EpoR) (1) HIF/HIF Prolyl-Hydroxylase (2) Interleukin Related (1) Isotope-Labeled Compounds (1) JAK (1) MMP (7) NF-κB (1) PI3K (1) Prostaglandin Receptor (1) Reactive Oxygen Species (ROS) (1) TNF Receptor (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (10) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (4)

By Targets:

Akt (1)

Angiotensin Receptor (1)

Biochemical Assay Reagents (1)

Bradykinin Receptor (1)

Calcium Channel (6)

CDK (1)

Cyclin G-associated Kinase (GAK) (1)

Drug Derivative (2)

Erythropoietin Receptor (EpoR) (1)

HIF/HIF Prolyl-Hydroxylase (2)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

JAK (1)

MMP (7)

NF-κB (1)

PI3K (1)

Prostaglandin Receptor (1)

Reactive Oxygen Species (ROS) (1)

TNF Receptor (1)

By Research Areas:

Cancer (1)

Cardiovascular Disease (10)

Inflammation/Immunology (4)

Metabolic Disease (2)

Neurological Disease (4)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14744A

Levamlodipine besylate 2 Publications Verification (S)-Amlodipine besylate; Levoamlodipine besylate	Calcium Channel MMP	Cardiovascular Disease
Levamlodipine ((S)-Amlodipine; Levoamlodipin) besylate is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine besylate significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine besylate not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine besylate exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine besylate may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine besylate can be used in research related to hypertension and atherosclerosis .

HY-14744

Levamlodipine 2 Publications Verification (S)-Amlodipine; Levoamlodipine	Calcium Channel MMP	Cardiovascular Disease Neurological Disease
Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .

HY-N7681

Taxifolin 7-O-β-D-glucoside 1 Publications Verification Taxifolin 7-O-glucoside	Biochemical Assay Reagents	Inflammation/Immunology
Taxifolin 7-O-β-D-glucoside (Taxifolin 7-O-glucoside) is a flavonol and active antioxidant that can be isolated from Scutellaria baicalensis. Taxifolin 7-O-β-D-glucoside participates in pathogen defense and ultraviolet damage protection in the seed coat during seed germination of Scutellaria baicalensis .

HY-W062700

STS-E412	JAK Erythropoietin Receptor (EpoR)	Neurological Disease
STS-E412 is a selective activator of tissue-protective EPO receptor (including EPOR and CD131). STS-E412 can be used for research of neurodegenerative diseases and organ protection .

HY-W392413

Glutathione monoethyl ester	Drug Derivative Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Glutathione monoethyl ester is a glutathione derivative that can be transported into cells and hydrolyzed into glutathione. Glutathione monoethyl ester downregulates the gene expression of TEN1 and CTC1 while upregulating TERT expression. Glutathione monoethyl ester enhances telomerase activity, promotes proliferation and differentiation in aged bone marrow stromal cells, while elevating glutathione levels and reducing oxidative stress, protein aggregation and cell death in motor neuronal cells. Glutathione monoethyl ester confers broad multi-organ protection against cerebral ischemia, renal injury, liver damage, and pancreatitis. Glutathione monoethyl ester can be used for the research of amyotrophic lateral sclerosis, stroke, acute renal failure, liver injury, and acute pancreatitis .

HY-169221

Perindopril arginine	Angiotensin Receptor	Cardiovascular Disease
Perindopril arginine is an angiotensin-converting enzyme inhibitor with hypotensive activity. Perindopril arginine is used to inhibit hypertension to lower blood pressure. Perindopril arginine, when used in combination with indapamide and amlodipine, can effectively lower blood pressure and provide better target organ protection .

HY-14744D

Levamlodipine besylate Hemipentahydrate	Calcium Channel MMP	Cardiovascular Disease Neurological Disease
Levamlodipine besylate Hemipentahydrate is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine besylate Hemipentahydrate significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine besylate Hemipentahydrate not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine besylate Hemipentahydrate exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine besylate Hemipentahydrate may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine besylate Hemipentahydrate can be used in research related to hypertension and atherosclerosis .

HY-112678

TM6008	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
TM6008 is a potent and orally active prolyl hydroxylase (PHD) inhibitor. TM6008 chelats transition metal (copper) and inhibits the autoxidation of ascorbic acid with an IC₅₀ value is 0.57 μM. TM6008 exerts organ protection against ischemia in vivo and can be used for cerebrovascular disease research .

HY-118543

TM6089	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
TM6089 is a unique Prolyl Hydroxylase (PHD) inhibitor which stimulates HIF activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia. Local administration of TM6089 enhances angiogenesis, and oral administration stimulates HIF activity in transgenic rats expressing a hypoxia-responsive reporter vector .

HY-14744B

Levamlodipine hydrochloride (S)-Amlodipine hydrochloride; Levoamlodipine hydrochloride	Calcium Channel MMP	Cardiovascular Disease
Levamlodipine ((S)-Amlodipine; Levoamlodipin) hydrochloride is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine hydrochloride significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine hydrochloride not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine hydrochloride exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine hydrochloride may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine hydrochloride can be used in research related to hypertension and atherosclerosis .

HY-14744S

Levamlodipine-d4 (S)-Amlodipine-d₄; Levoamlodipine-d₄	Isotope-Labeled Compounds Calcium Channel MMP	Others
Levamlodipine-d₄ is the deuterium labeled Levamlodipine. Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .

HY-14744C

Levamlodipine hydrobromide (S)-Amlodipine hydrobromide; Levoamlodipine hydrobromide	Calcium Channel MMP	Cardiovascular Disease Others
Levamlodipine ((S)-Amlodipine; Levoamlodipin) hydrobromide is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine hydrobromide significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine hydrobromide not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine hydrobromide exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine hydrobromide may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine hydrobromide can be used in research related to hypertension and atherosclerosis .

HY-118945

FR191413	Prostaglandin Receptor Bradykinin Receptor	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FR191413 is a selective bradykinin B2 receptor agonist that stimulates prostaglandin E2 production in WI-38 cells and activates BK B2 receptor-mediated pathways such as vasodilation and organ protection. FR191413 competitively binds to [ ³H]-BK in guinea pig ileum (GPI) membranes and CHO cells transfected with the human BK B2 receptor, with IC₅₀ values of 20.0 nM and 2.60 nM, respectively. FR191413 can be used in research related to cardiovascular diseases and diabetes, including hypertension, myocardial hypertrophy, myocardial infarction, arrhythmias, and diabetic nephropathy .

HY-114214

CKD-712	Drug Derivative NF-κB MMP TNF Receptor Interleukin Related Cyclin G-associated Kinase (GAK) CDK PI3K Akt	Inflammation/Immunology Cancer
CKD-712 is an orally active multi-target tetrahydroisoquinoline derivatived and a potent inhibitor of the NF-κB pathway . CKD-712 selectively inhibits MMP-9 with no effect on MMP-2, downregulates the expression of TNF-α, IL-6, cyclin A, cyclin B, CDK-1 and other proteins, and activates the PI3K/Akt signaling pathway . CKD-712 blocks the activation and nuclear translocation of NF-κB, downregulates inflammatory factors and pro-tumor metastatic proteins, and induces G2/M phase arrest in tumor cells and thereby inhibits the invasion of cancer cells . CKD-712 can be used for the research of sepsis, myocardial ischemia-reperfusion injury and non-small cell lung cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7681

Taxifolin 7-O-β-D-glucoside 1 Publications Verification Taxifolin 7-O-glucoside	Flavanonols Structural Classification Flavonoids Classification of Application Fields Cercis chinensis Bunge Other Diseases Phenols Polyphenols Plants Compositae Disease Research Fields Source Classification	Biochemical Assay Reagents
Taxifolin 7-O-β-D-glucoside (Taxifolin 7-O-glucoside) is a flavonol and active antioxidant that can be isolated from Scutellaria baicalensis. Taxifolin 7-O-β-D-glucoside participates in pathogen defense and ultraviolet damage protection in the seed coat during seed germination of Scutellaria baicalensis .

Cat. No.	Product Name	Chemical Structure

HY-14744S

Levamlodipine-d4
Levamlodipine-d₄ is the deuterium labeled Levamlodipine. Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .

Levamlodipine-d4

Levamlodipine-d₄ is the deuterium labeled Levamlodipine. Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks